NYU Langone's Perlmutter Cancer Center | Strategic Alliance Partners

Bhavana Pothuri, MD, discusses the use of antibody-drug conjugates in patients with ovarian cancer and AEs to be aware of when treating patients with these therapies.

Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.

Luis Raez, MD, offers insights on how co-mutations in STK11 or KEAP1 impact the use of immunotherapies in KRAS G12C–mutant non–small cell lung cancer.

Bhavana Pothuri, MD, discusses treatment considerations for patients in tough-to-treat subgroups of ovarian cancer based on currently available data.

Key opinion leaders in multiple myeloma management elucidate the value of clinical trials and share enthusiasm for improving enrollment when possible.

A focused discussion on the regulatory aspects of drug testing and approval, globally, with respect to the setting of multiple myeloma management.

In this third episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, share how they would best utilize genetic testing results obtained from endoscopic ultrasound–guided biopsies in pancreatic ductal adenocarcinomas.

Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.

Expert panelists review the CodeBreaK trials focused on sotorasib in the treatment of patients with KRAS G12C-mutant non–small cell lung cancer.

Expert panelists consider best methods in educating patients on their options for therapy following a diagnosis of multiple myeloma.

Comprehensive insight to disparities that may impact a patient’s access to therapy for multiple myeloma and how these may be overcome.

Bhavana Pothuri, MD, discusses the promise of the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.

In this second episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, discuss the techniques used such as endoscopic ultrasound–guided biopsies to collect adequate tissue to perform genomic analyses in pancreatic cancer, and the likelihood for finding actionable mutations in this population.

Shared insight on the use of first-generation EGFR tyrosine kinase inhibitors and the role of immunotherapy in treating patients with NSCLC with uncommon EGFR mutations.

Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations.

Panelists share a brief discussion on the current treatment armamentarium available to patients with newly diagnosed multiple myeloma.

Experts in multiple myeloma management consider essential tests that aid in the diagnosis and treatment of newly presenting patients.

In this first episode of OncChats: Leveraging Endoscopic Ultrasound in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Tamas A. Gonda, MD, discuss how endoscopic ultrasound has changed the diagnosis of pancreatic cancer and how it may also be utilized to guide personalized treatment in nonmetastatic adenocarcinomas.

Key opinion leaders on non–small cell lung cancer review treatment options for patients with EGFR mutations.

Experts on non–small cell lung cancer discuss strategies to improve molecular testing and opportunities for community physicians to reach out to expert oncologists for clinical insights.

Bhavana Pothuri, MD, discusses the phase 3 NRG-GY018 and RUBY trials in patients with endometrial cancer.

Antonia Sepulveda, MD, PhD, an expert on NSCLC, outlines discrepancies in molecular testing between academic and community settings.

Focused discussion on tissue testing and the effect of turnaround time on NSCLC treatment and molecular testing strategies.

Shared insight from key opinion leaders on educational resources made available to physicians and patients, respectively, regarding multiple myeloma management.

Opening its discussion on key unmet needs in multiple myeloma management, a panel of experts discuss key challenges faced when diagnosing patients with multiple myeloma and review the impact of having a multidisciplinary care team.

Expert oncologists compare the logistics and sensitivities of liquid and tissue biopsies in the treatment of non–small cell lung cancer.

A panel of experts on the treatment of non–small cell lung cancer (NSCLC) discuss the role of biomarker testing and review testing strategies.

The panel looks to the future and offers closing thoughts on the evolving treatment landscape in endometrial cancer.

An overview of ongoing research in the endometrial cancer treatment space.

The expert panel reviews the KEYNOTE-775 trial, which focused on lenvatinib and pembrolizumab in advanced endometrial cancer.